Project Grant R01HL171226
- This $387,116 Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) supports research at the University of South Florida to investigate the sensory neuronal mechanisms underlying the development of house dust mite-induced airway hyperreactivity, a key characteristic of asthma. The long-term goal is to define the neural mechanisms triggered by house dust mite exposure that lead to the development of airway...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,436,586 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the San Diego Biomedical Research Institute. The purpose of this 24-month project is to assess the role of a novel subset of cytotoxic CD4+ T cells (CD4-CTLs) in severe asthma pathogenesis and response to Type 2 (T2) biologic therapies. Led by a multidisciplinary team, the INSIGHTS study will analyze airway CD4-CTLs from 160 severe asthma...
- This $2,456,717 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to exploit emerging ideas in G protein-coupled receptor biology and pharmacology to treat asthma. The award supports a highly collaborative research team at Thomas Jefferson University's Sidney Kimmel Medical College to pursue three key goals: 1) identify novel targets and targeting molecules involving G protein-coupled receptor...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $650,079 Project Grant to Northeastern University under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant supports the development and optimization of novel small-molecule probes targeting the alpha9 nicotinic acetylcholine receptor (α9*-nAChR) subunit, with the goal of exploring its potential for pain management. The 5-year project aims to advance...
- This Project Grant award for $185,866.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) supports research to modulate airway epithelial syndecan-1 in a preclinical model of steroid-resistant asthma. The research aims to examine the role of syndecan-1 and its cleavage by the enzyme heparanase in driving inflammation and glucocorticoid resistance in severe allergic asthma. The study...
- This Project Grant award of $472,592 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will support research to evaluate RGIA5474, a peripherally-restricted and highly selective a9a10 nicotinic acetylcholine receptor (nAChR) antagonist, as a potential novel treatment for migraine. The researchers from the New York Institute of Technology (NYIT) hypothesize that blocking...
- This Project Grant award of $154,980 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at Seattle Children's Hospital to investigate circadian regulation of epithelial immune responses in asthma. The key activities include: Measuring viral replication and innate immune responses in airway epithelial cell cultures from healthy donors and pediatric asthma patients in relation to cellular circadian time. Comparing circadian gene...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $260,445 to Brigham & Women's Hospital Inc. to conduct research on identifying biomarkers associated with nasal polyp recurrence in patients with aspirin-exacerbated respiratory disease (AERD). The key objectives are to: 1) Establish a biomarker-based predictive model for nasal polyp recurrence in AERD patients,...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $228,000 to Kansas State University to study the role of nociceptor sensory neurons and neuropeptide signaling in modulating host immune responses to pneumonic sepsis caused by carbapenem-resistant Klebsiella pneumoniae (CRKP) infections. The research aims to elucidate how nociceptor neurons and their neuropeptide...
- This Project Grant award for $355,935 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) supports the development of a novel, oral immunoregulatory therapeutic for the treatment of asthma. The primary objectives are to characterize the therapeutic efficacy and dosing regimen of the compound in mouse models of asthma, and to evaluate its ability to modulate immune function and suppress inflammation in human...
MECHANISMS OF TACHYKINERGIC NERVE-MEDIATED SEVERE BRONCHOCONSTRICTION AND INFLAMMATION - PROJECT SUMMARY SUBSTANCE P IS A SENSORY NERVE TACHYKININ NEUROPEPTIDE CAPABLE OF INDUCING BRONCHOCONSTRICTION AND INFLAMMATION. WE HAVE RECENTLY SHOWN THAT AIRWAY SENSORY NERVE DENSITY AND NEURONAL SUBSTANCE P EXPRESSION ARE SIGNIFICANTLY INCREASED IN HUMANS WITH EOSINOPHILIC ASTHMA. WE HAVE ALSO DEMONSTRATED THAT MICE BORN TO ALLERGEN-SENSITIZED MOTHERS OR TRANSGENIC MOTHERS WITH ELEVATED INTERLEUKIN-5 (A PRIMARY CYTOKINE INVOLVED IN EOSINOPHIL MATURATION AND SURVIVAL) RECAPITULATE KEY FEATURES OF HUMAN ASTHMA INCLUDING INCREASED AIRWAY SENSORY NERVE DENSITY AND SUBSTANCE P EXPRESSION. WHEN THESE OFFSPRING ARE EXPOSED TO ALLERGEN, THEY DEVELOP LETHAL BRONCHOCONSTRICTION THAT IS RESCUED BY ANTAGONISTS OF SUBSTANCE P'S TARGET, NEUROKININ-1 RECEPTORS. THE CENTRAL HYPOTHESIS OF THIS PROPOSAL IS THAT INCREASED AIRWAY SUBSTANCE P INNERVATION CAUSES LETHAL BRONCHOCONSTRICTION AND POTENTIATES EOSINOPHILIC INFLAMMATION AFTER ALLERGEN CHALLENGE. IN THIS PROPOSAL, WE WILL DETERMINE THE MECHANISM BY WHICH SUBSTANCE P MEDIATES THESE EFFECTS USING BOTH CRE-RECOMBINASE AND PHARMACOLOGIC METHODOLOGY TO 1) TEST THE ROLE OF NK1 RECEPTORS ON SPECIFIC AIRWAY NERVE SUBTYPES (SENSORY AND PARASYMPATHETIC NERVES) AND SMOOTH MUSCLE 2) TEST THE ROLE OF NK1 RECEPTORS AND A NOVEL SUBSTANCE P RECEPTOR, MRGPRA1, ON AIRWAY DENDRITIC CELLS AND 3) TEST THE ROLE OF NK1 RECEPTORS ON AIRWAY EOSINOPHILS BOTH IN ISOLATION, AND SYNERGISTICALLY WITH CCR3 (THE TARGET OF EOTAXIN, A POTENT EOSINOPHIL CHEMOATTRACTANT). ENDPOINTS INCLUDE MEASUREMENT OF AIRWAY RESPONSIVENESS IN VIVO, EOSINOPHIL AND DENDRITIC CELL ACTIVATION USING FLOW CYTOMETRY, AND QUANTITATIVE ASSESSMENTS OF AIRWAY NERVE DENSITY, SUBSTANCE P EXPRESSION, AND EOSINOPHIL AND DENDRITIC CELL INTERACTIONS WITH NERVES USING NOVEL 3D CONFOCAL MICROSCOPY DEVELOPED BY OUR GROUP. RESULTS WILL IDENTIFY NOVEL PATHWAYS AND DRUG TARGETS IN SEVERE ASTHMA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $77.6k | 6/26/25 | ||
| Not listed | $698.1k | 4/17/25 | ||
| Not listed | $698.1k | 4/17/25 | ||
| Not listed | $769.6k | 6/10/24 | ||
| Not listed | $769.6k | 6/10/24 |